Literature DB >> 36072699

Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013.

Alice Y Guh1, Sarah H Yi1, James Baggs1, Lisa Winston2, Erin Parker3, Helen Johnston4, Elizabeth Basiliere4, Danyel Olson5, Scott K Fridkin6, Nirja Mehta6, Lucy Wilson7, Rebecca Perlmutter8, Stacy M Holzbauer9,10, Paige D'Heilly9, Erin C Phipps11, Kristina G Flores11, Ghinwa K Dumyati12, Trupti Hatwar12, Rebecca Pierce13, Valerie L S Ocampo13, Christopher D Wilson14, Jasmine J Watkins14, Lauren Korhonen1, Ashley Paulick1, Michelle Adamczyk1, Dale N Gerding15, Sujan C Reddy1.   

Abstract

Among persons with an initial Clostridioides difficile infection (CDI) across 10 US sites in 2018 compared with 2013, 18.3% versus 21.1% had ≥1 recurrent CDI (rCDI) within 180 days. We observed a 16% lower adjusted risk of rCDI in 2018 versus 2013 (P < .0001). Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Entities:  

Keywords:  Clostridioides difficile; infection; recurrent

Year:  2022        PMID： 36072699      PMCID： PMC9439575          DOI： 10.1093/ofid/ofac422

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN： 2328-8957            Impact factor:   4.423


  16 in total

1.  Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.

Authors:  Steven W Johnson; Shannon V Brown; David H Priest
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

Review 2.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Recurrent Clostridium difficile infection is associated with increased mortality.

Authors:  M A Olsen; Y Yan; K A Reske; M D Zilberberg; E R Dubberke
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

4.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

Review 5.  Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis.

Authors:  Alberto Enrico Maraolo; Maria Mazzitelli; Emanuela Zappulo; Riccardo Scotto; Guido Granata; Roberto Andini; Emanuele Durante-Mangoni; Nicola Petrosillo; Ivan Gentile
Journal:  Antibiotics (Basel)       Date:  2022-01-30

6.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

Authors:  Alice Y Guh; Yi Mu; Lisa G Winston; Helen Johnston; Danyel Olson; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

7.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Authors:  Fred A Zar; Srinivasa R Bakkanagari; K M L S T Moorthi; Melinda B Davis
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

8.  Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.

Authors:  Elaine Finn; Fredrik L Andersson; Matthew Madin-Warburton
Journal:  BMC Infect Dis       Date:  2021-05-19       Impact factor: 3.090

9.  Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations.

Authors:  Fernanda C Lessa; Yi Mu; Lisa G Winston; Ghinwa K Dumyati; Monica M Farley; Zintars G Beldavs; Kelly Kast; Stacy M Holzbauer; James I Meek; Jessica Cohen; L Clifford McDonald; Scott K Fridkin
Journal:  Open Forum Infect Dis       Date:  2014-07-28       Impact factor: 3.835

10.  Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile.

Authors:  Warren N Fawley; C W Knetsch; Duncan R MacCannell; Celine Harmanus; Tim Du; Michael R Mulvey; Ashley Paulick; Lydia Anderson; E J Kuijper; Mark H Wilcox
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.